Date: 2015-09-16
Type of information: Nomination
Compound:
Company: Medivir (Sweden)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination restructuring
Action mechanism:
Disease:
Details: * On September 16, 2015, Medivir announced that, as the next step in the company's optimisation process, its research and development operations will be merged into a joint unit as of 1 October 2015, headed by Richard Bethell who will hold the new title of EVP Research & Development. The new unit will span the entire process, from the early research to the late-stage development phases.
Medivir will also create a new function to house all regulatory skills and areas of responsibility, headed by Åsa Holmgren who will hold the new title of EVP Strategic Regulatory Affairs. Åsa, who was recently recruited to the company, hereby becomes a member of Medivir's management group. In light of the reorganization process, Charlotte Edenius, EVP Development, has chosen to take on new challenges outside Medivir.
Financial terms:
Latest news:
